The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antifungal infection Therapeutics Market Research Report 2025
Synopsis
Antifungal drugs are used to treat infections caused by fungus and to prevent the development of fungal infections in patients with weakened immune systems.
The global Antifungal infection Therapeutics market was valued at US$ 18650 million in 2023 and is anticipated to reach US$ 29440 million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antifungal infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antifungal infection Therapeutics.
Report Scope
The Antifungal infection Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antifungal infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antifungal infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Scynexis
Sanofi-Aventis
Pfizer
Novartis
Merck & Co
Kramer Laboratories
Johnson & Johnson
ID Sigma-Aldrich Corporation
Glenmark Pharmaceuticals
Glaxosmithkline
Enzon Pharmaceuticals
Bayer Healthcare
Astellas Pharma
Asperqillus
Alternaria
Abbott Laboratories
Segment by Type
Polyenes
Echinocandins
Azoles
Allylamines
Other Drug types
Segment by Application
Hospitals and Clinics
Dermatology Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antifungal infection Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antifungal drugs are used to treat infections caused by fungus and to prevent the development of fungal infections in patients with weakened immune systems.
The global Antifungal infection Therapeutics market was valued at US$ 18650 million in 2023 and is anticipated to reach US$ 29440 million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antifungal infection Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antifungal infection Therapeutics.
Report Scope
The Antifungal infection Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antifungal infection Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antifungal infection Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Scynexis
Sanofi-Aventis
Pfizer
Novartis
Merck & Co
Kramer Laboratories
Johnson & Johnson
ID Sigma-Aldrich Corporation
Glenmark Pharmaceuticals
Glaxosmithkline
Enzon Pharmaceuticals
Bayer Healthcare
Astellas Pharma
Asperqillus
Alternaria
Abbott Laboratories
Segment by Type
Polyenes
Echinocandins
Azoles
Allylamines
Other Drug types
Segment by Application
Hospitals and Clinics
Dermatology Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antifungal infection Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antifungal infection Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Polyenes
1.2.3 Echinocandins
1.2.4 Azoles
1.2.5 Allylamines
1.2.6 Other Drug types
1.3 Market by Application
1.3.1 Global Antifungal infection Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Dermatology Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antifungal infection Therapeutics Market Perspective (2019-2030)
2.2 Antifungal infection Therapeutics Growth Trends by Region
2.2.1 Global Antifungal infection Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antifungal infection Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Antifungal infection Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Antifungal infection Therapeutics Market Dynamics
2.3.1 Antifungal infection Therapeutics Industry Trends
2.3.2 Antifungal infection Therapeutics Market Drivers
2.3.3 Antifungal infection Therapeutics Market Challenges
2.3.4 Antifungal infection Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antifungal infection Therapeutics Players by Revenue
3.1.1 Global Top Antifungal infection Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Antifungal infection Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Antifungal infection Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antifungal infection Therapeutics Revenue
3.4 Global Antifungal infection Therapeutics Market Concentration Ratio
3.4.1 Global Antifungal infection Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antifungal infection Therapeutics Revenue in 2023
3.5 Antifungal infection Therapeutics Key Players Head office and Area Served
3.6 Key Players Antifungal infection Therapeutics Product Solution and Service
3.7 Date of Enter into Antifungal infection Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antifungal infection Therapeutics Breakdown Data by Type
4.1 Global Antifungal infection Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Antifungal infection Therapeutics Forecasted Market Size by Type (2025-2030)
5 Antifungal infection Therapeutics Breakdown Data by Application
5.1 Global Antifungal infection Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Antifungal infection Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antifungal infection Therapeutics Market Size (2019-2030)
6.2 North America Antifungal infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antifungal infection Therapeutics Market Size by Country (2019-2024)
6.4 North America Antifungal infection Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antifungal infection Therapeutics Market Size (2019-2030)
7.2 Europe Antifungal infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antifungal infection Therapeutics Market Size by Country (2019-2024)
7.4 Europe Antifungal infection Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antifungal infection Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Antifungal infection Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antifungal infection Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Antifungal infection Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antifungal infection Therapeutics Market Size (2019-2030)
9.2 Latin America Antifungal infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antifungal infection Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Antifungal infection Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antifungal infection Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Antifungal infection Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antifungal infection Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Antifungal infection Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Scynexis
11.1.1 Scynexis Company Detail
11.1.2 Scynexis Business Overview
11.1.3 Scynexis Antifungal infection Therapeutics Introduction
11.1.4 Scynexis Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.1.5 Scynexis Recent Development
11.2 Sanofi-Aventis
11.2.1 Sanofi-Aventis Company Detail
11.2.2 Sanofi-Aventis Business Overview
11.2.3 Sanofi-Aventis Antifungal infection Therapeutics Introduction
11.2.4 Sanofi-Aventis Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.2.5 Sanofi-Aventis Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Antifungal infection Therapeutics Introduction
11.3.4 Pfizer Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Antifungal infection Therapeutics Introduction
11.4.4 Novartis Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Merck & Co
11.5.1 Merck & Co Company Detail
11.5.2 Merck & Co Business Overview
11.5.3 Merck & Co Antifungal infection Therapeutics Introduction
11.5.4 Merck & Co Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.5.5 Merck & Co Recent Development
11.6 Kramer Laboratories
11.6.1 Kramer Laboratories Company Detail
11.6.2 Kramer Laboratories Business Overview
11.6.3 Kramer Laboratories Antifungal infection Therapeutics Introduction
11.6.4 Kramer Laboratories Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.6.5 Kramer Laboratories Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Antifungal infection Therapeutics Introduction
11.7.4 Johnson & Johnson Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 ID Sigma-Aldrich Corporation
11.8.1 ID Sigma-Aldrich Corporation Company Detail
11.8.2 ID Sigma-Aldrich Corporation Business Overview
11.8.3 ID Sigma-Aldrich Corporation Antifungal infection Therapeutics Introduction
11.8.4 ID Sigma-Aldrich Corporation Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.8.5 ID Sigma-Aldrich Corporation Recent Development
11.9 Glenmark Pharmaceuticals
11.9.1 Glenmark Pharmaceuticals Company Detail
11.9.2 Glenmark Pharmaceuticals Business Overview
11.9.3 Glenmark Pharmaceuticals Antifungal infection Therapeutics Introduction
11.9.4 Glenmark Pharmaceuticals Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.9.5 Glenmark Pharmaceuticals Recent Development
11.10 Glaxosmithkline
11.10.1 Glaxosmithkline Company Detail
11.10.2 Glaxosmithkline Business Overview
11.10.3 Glaxosmithkline Antifungal infection Therapeutics Introduction
11.10.4 Glaxosmithkline Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.10.5 Glaxosmithkline Recent Development
11.11 Enzon Pharmaceuticals
11.11.1 Enzon Pharmaceuticals Company Detail
11.11.2 Enzon Pharmaceuticals Business Overview
11.11.3 Enzon Pharmaceuticals Antifungal infection Therapeutics Introduction
11.11.4 Enzon Pharmaceuticals Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.11.5 Enzon Pharmaceuticals Recent Development
11.12 Bayer Healthcare
11.12.1 Bayer Healthcare Company Detail
11.12.2 Bayer Healthcare Business Overview
11.12.3 Bayer Healthcare Antifungal infection Therapeutics Introduction
11.12.4 Bayer Healthcare Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.12.5 Bayer Healthcare Recent Development
11.13 Astellas Pharma
11.13.1 Astellas Pharma Company Detail
11.13.2 Astellas Pharma Business Overview
11.13.3 Astellas Pharma Antifungal infection Therapeutics Introduction
11.13.4 Astellas Pharma Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.13.5 Astellas Pharma Recent Development
11.14 Asperqillus
11.14.1 Asperqillus Company Detail
11.14.2 Asperqillus Business Overview
11.14.3 Asperqillus Antifungal infection Therapeutics Introduction
11.14.4 Asperqillus Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.14.5 Asperqillus Recent Development
11.15 Alternaria
11.15.1 Alternaria Company Detail
11.15.2 Alternaria Business Overview
11.15.3 Alternaria Antifungal infection Therapeutics Introduction
11.15.4 Alternaria Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.15.5 Alternaria Recent Development
11.16 Abbott Laboratories
11.16.1 Abbott Laboratories Company Detail
11.16.2 Abbott Laboratories Business Overview
11.16.3 Abbott Laboratories Antifungal infection Therapeutics Introduction
11.16.4 Abbott Laboratories Revenue in Antifungal infection Therapeutics Business (2019-2024)
11.16.5 Abbott Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
